Hoth Therapeutics (HOTH) announced breakthrough preclinical findings demonstrating the efficacy of HT-KIT, a novel targeted ...

Treatment with pimitespib was associated with stable disease in two-thirds of patients with advanced gastrointestinal stromal ...

A study shows that high-grade glioma tumor cells harboring DNA alterations in the gene PDGFRA responded to the drug avapritinib, which is already approved by the United States Food and Drug ...

Gleevec response in GIST varies by mutational profile, with KIT-exon-11 mutation linked to better outcomes, emphasizing ...

(RTTNews) - Hoth Therapeutics, Inc. (HOTH) Tuesday announced positive preclinical results for HT-KIT, a novel targeted therapy for gastrointestinal stromal tumors (GIST). GIST is a rare but ...

Hoth Therapeutics announces positive preclinical results for HT-KIT in aggressive cancer gastrointestinal stromal tumours: New York Wednesday, March 19, 2025, 18:00 Hrs [IST] Hoth ...

Researcher suggests compounds secreted by high-risk MSCs that are detectable in the bloodstream could act as biomarkers for ...

Hoth Therapeutics Inc. has released preclinical findings demonstrating the efficacy of HT-KIT, a novel targeted therapy for gastrointestinal stromal tumors (GIST).

This weekend church members of St. Paul Lutheran Church in Wisner are helping put on a benefit to help Pastor Jared Hartman ...

High-grade glioma, a difficult-to-treat and aggressive form of pediatric and adult brain cancer, responded to FDA-approved avapritinib. | Drug Discovery And Development ...

A company presentation will take place during the conference’s Innovation track on Friday, March 28th at 9:00am. NeauxCancer conference’s Innovation track spotlights the most promising emerging ...

which is already approved by the United States Food and Drug Administration to treat gastrointestinal stromal tumors with a PDGFRA exon 18 mutation as well advanced systemic mastocytosis and ...